BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 18037232)

  • 1. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
    Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
    Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.
    Komiya T; Hosono Y; Hirashima T; Masuda N; Yasumitsu T; Nakagawa K; Kikui M; Ohno A; Fukuoka M; Kawase I
    Clin Cancer Res; 1997 Oct; 3(10):1831-5. PubMed ID: 9815570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
    Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
    Lung Cancer; 2005 Dec; 50(3):309-17. PubMed ID: 16125276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
    Volm M; Koomägi R
    Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis.
    Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Donati V; Fontanini G
    Cancer Invest; 2008 Mar; 26(2):168-72. PubMed ID: 18259947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
    Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
    Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
    Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer.
    Shih CM; Lee YL; Chiou HL; Chen W; Chang GC; Chou MC; Lin LY
    Lung Cancer; 2006 Apr; 52(1):15-20. PubMed ID: 16476505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
    Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer.
    Shih CM; Lee YL; Chiou HL; Hsu WF; Chen WE; Chou MC; Lin LY
    Lung Cancer; 2005 Dec; 50(3):291-7. PubMed ID: 16122836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
    Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
    Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer.
    Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H
    Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.